In a report released yesterday, Raju Prasad from William Blair maintained a Buy rating on Audentes Therapeutics (NASDAQ: BOLD). The company’s shares closed yesterday at $37.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 25.0% and a 61.1% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Spark Therapeutics, and PTC Therapeutics.
Currently, the analyst consensus on Audentes Therapeutics is Moderate Buy and the average price target is $31.50, representing a -14.9% downside.
In a report issued on May 2, H.C. Wainwright also reiterated a Buy rating on the stock with a $37 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $41.80 and a one-year low of $13.90. Currently, Audentes Therapeutics has an average volume of 322.5K.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.
